15644
document
The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase . BACKGROUND Sublingual administration of allergens is a safe and effective alternative to subcutaneous immunotherapy in patients with respiratory allergies . A drawback to this therapeutic approach is the relatively long and complex management of the induction phase . AIM OF THE STUDY To determine whether different induction regimens affect the outcome of sublingual immunotherapy . METHODS AND RESULTS Adult and pediatric patients with allergic rhinoconjunctivitis and/or asthma were included in the study . Ten subjects served as controls and received symptomatic treatments . Forty-three subjects were allocated to sublingual immunotherapy , with three different induction protocols ( 8- , 15- and 20-day , respectively ) . Symptom and medication scores , skin test results and ( in asthmatic patients ) FEV1 values were monitored for two years . Adverse effects were recorded . All induction regimens produced a significant improvement in symptom and medication usage ( p < 0.0001 ) ; skin test scores decreased ( p < 0.0001 ) and FEV1 improved ( p < 0.05 ) . In contrast , symptom and skin test scores did not significantly change in controls . No relevant adverse effects were observed with any of the induction regimens . CONCLUSIONS For patients with respiratory allergies , sublingual immunotherapy with an 8-day induction protocol is safe and effective . Our results encourage the usage of shorter induction regimens , which produce better compliance with this therapy .
15645
Intervention_Pharmacological
sublingual immunotherapy
15646
Intervention_Pharmacological
Sublingual administration of allergens
15647
Intervention_Pharmacological
sublingual immunotherapy
15648
Intervention_Control
symptomatic treatments
15649
Intervention_Pharmacological
sublingual immunotherapy
15650
Intervention_Pharmacological
sublingual immunotherapy
15651
Outcome_Physical
Symptom and medication scores
15652
Outcome_Physical
skin test results
15653
Outcome_Physical
( in asthmatic patients ) FEV1 values
15654
Outcome_Adverse-effects
Adverse effects
15655
Outcome_Physical
significant improvement in symptom and medication usage
15656
Outcome_Physical
skin test scores decreased
15657
Outcome_Physical
FEV1 improved
15658
Outcome_Physical
symptom and skin test scores did not
15659
Outcome_Other
change
15660
Outcome_Adverse-effects
adverse effects
15661
Participant_Condition
patients with respiratory allergies .
15662
Participant_Condition
Adult and pediatric patients with allergic rhinoconjunctivitis and/or asthma were included in the study .